Judge Denies Teva Pharmaceuticals motion to dismiss Corcept Therapeutics allegations of patent infringement

Judge Denies Teva Pharmaceuticals motion to dismiss Corcept Therapeutics allegations of patent infringement

Wednesday, October 24, 2018

 

DrugName : mifepristone

Corcept Therapeutics Incorporated, a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced that Judge Susan Wigenton of the United States District Court for the District of New Jersey has denied Teva Pharmaceuticals USA, Inc.’s motion to dismiss a lawsuit brought by Corcept alleging infringement of patents relating to the use of Korlym, Corcept’s medication for the treatment of patients with endogenous Cushing’s syndrome.

Corcept has sued Teva for infringement of two patents covering Korlym upon receipt of notice in February 2018 that Teva is seeking approval from the United States Food & Drug Administration to market a generic version of Korlym. In July 2018, Corcept filed an amended complaint asserting a third patent against Teva. Judge Wigenton’s denial of Teva’s motion means that Corcept’s lawsuit will proceed.

“We are gratified by today’s decision,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer, “and look forward to developing and presenting our case to the Court. We will vigorously enforce our intellectual property rights.”,

Key Facts

    •  News Category

      Intellectual Property
      Legal And Regulatory
      Other Product News
      Product Development

    •  Company

      Teva Pharmaceuticals USA Inc    and   Corcept Therapeutics Inc

    •  Country

      North America > United States of America

Leave a Reply

Your email address will not be published. Required fields are marked *

+ 6 = 10